ALOX5 and COVID-19: Regarding the lipoxygenase biosynthetic pathway, we did not detect changes in the levels of ALOX5 or 12 between the different severity groups, unlike ALOX15, which was repressed in all COVID-19 patients, regardless of their severity (Figure 2A).